Year: 2018
Type: dissertation
Abstract: Haematological malignancies (HM) are a diverse group of relatively rare, but often life-threatening cancers. Over 900 000 people worldwide are expected to receive a HM diagnosis in 2018. Most types of HM have an increasing \nincidence with age, which is often associated with poor survival due to the inadequate treatment options available. Two types of HM with a particularly poor outlook are acute myeloid leukaemia (AML), which is an acute cancer of immature myeloid blood cells, and multiple myeloma (MM) which is an incurable malignancy with primary focus in the bone marrow (BM). \n \nOncolytic viruses (OV) preferentially infect and kill malignantly transformed cells. OV therapy (OVT) is a promising treatment strategy which has recently been approved for clinical use in the treatment of melanoma. In addition to direct lytic killing, the induction of an anti-tumour immune response is thought to be essential for efficient OVT with establishment of long-term protection against tumour recurrence. While research efforts into OVT for solid malignancies have seen a surge in recent years, HM remains under-investigated in this context, in particular with regards to the anti-tumour \nimmune response. Thus, the overall aim of this study was to examine the role of OV-induced anti-tumour immunity in HM. \n \nTwo OV were evaluated in the context of MM; both reovirus and coxsackievirus A21 (CVA21) were found to induce anti-tumour immune responses in vitro comprising cytokine-mediated killing, natural killer cellmediated cytotoxicity, and the generation of tumour-specific cytotoxic T cells. Moreover, reovirus treatment showed efficacy in an immunocompetent in vivo model, along with evidence of the onset of an immune response primarily in the spleen. \n \nPivotally, this study is the first to evaluate CVA21 as a treatment for AML. CVA21 was able to induce anti-tumour immunity in AML in vitro using both AML cell lines and a cohort of primary AML samples, despite resistance to lytic killing. Furthermore, examination of peripheral blood samples from patients with solid malignancies following intravenous administration of CVA21 provided “proof of principle” evidence that CVA21 was able to \nactivate immune cells in the peripheral circulation in a state of malignancy, which is crucial for the future development of CVA21 OVT. \n \nThe obtained results also established the cellular mechanisms responsible for CVA21-induced anti-tumour immunity. Plasmacytoid dendritic cells were identified as the main detectors of CVA21 infection and were responsible for orchestrating both innate and adaptive anti-tumour immune responses. These findings provide novel insights into the immunobiology of CVA21 with \nimportance for the continued clinical development of this OV. \n \nIn conclusion, this study has demonstrated that OVT, as a well-tolerated, specific, and long-lasting therapy, has the potential to improve the treatment of both MM and AML through the induction of a multi-component anti-tumour immune response.
Author: Louise Marie Erika Müller
Institution: University of Leeds
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: oncolytic virotherapy, antitumor immunity, hematologic malignancies, acute myeloid leukemia, multiple myeloma, coxsackievirus A21, reovirus, NK cell cytotoxicity, tumor microenvironment, tumour-associated macrophages, tumor-associated neutrophils, tumor-associated B cells, tumor-associated T cells, tumor-associated dendritic cells, cancer-associated fibroblasts
Open Access status: green
OpenAlex ID: W2955254189
